Fate Therapeutics Inc [FATE] stock is trading at $1.87, up 3.89%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FATE shares have gain 16.15% over the last week, with a monthly amount drifted -26.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fate Therapeutics Inc [NASDAQ: FATE] stock has seen the most recent analyst activity on November 18, 2024, when BofA Securities upgraded its rating to a Neutral. Previously, Piper Sandler upgraded its rating to Overweight on June 17, 2024, and elevated its price target to $6. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $7 on January 24, 2023. Wedbush downgraded its rating to a Neutral and reduced its price target to $7 on January 06, 2023. Truist downgraded its rating to Hold for this stock on January 06, 2023, and downed its price target to $7. In a note dated January 06, 2023, Stifel downgraded an Hold rating on this stock and revised its target price from $107 to $5.30.
Fate Therapeutics Inc [FATE] stock has fluctuated between $1.55 and $8.83 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $1.87 at the most recent close of the market. An investor can expect a potential return of 167.38% based on the average FATE price forecast.
Analyzing the FATE fundamentals
Fate Therapeutics Inc [NASDAQ:FATE] reported sales of 13.45M for the trailing twelve months, which represents a growth of 58.13%. Gross Profit Margin for this corporation currently stands at -2.3% with Operating Profit Margin at -14.62%, Pretax Profit Margin comes in at -13.25%, and Net Profit Margin reading is -13.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.46 and Total Capital is -0.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7700 points at the first support level, and at 1.6700 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9800, and for the 2nd resistance point, it is at 2.0900.
Ratios To Look Out For
For context, Fate Therapeutics Inc’s Current Ratio is 8.29. In addition, the Quick Ratio stands at 8.29 and the Cash Ratio stands at 1.01. Considering the valuation of this stock, the price to sales ratio is 15.92, the price to book ratio is 0.59.
Transactions by insiders
Recent insider trading involved Redmile Group, LLC, Director, that happened on Dec 20 ’24 when 0.4 million shares were purchased. Director, Redmile Group, LLC completed a deal on Dec 20 ’24 to sell 0.34 million shares. Meanwhile, Director, 10% Stockholder Redmile Group, LLC bought 0.34 million shares on Dec 20 ’24.
